A Paradigm Shift In Managing Migraines

At Asembia 2018, SPC Editorial Director David Bronstein sat down with Dawn C. Buse, PhD, a clinical professor of neurology, at Albert Einstein College of Medicine, in New York City, and an expert on headaches. They discussed a new class of drugs to prevent migraines in adults. The FDA recently approved the first of these—erenumab-aooe (Aimovig, Amgen/Novartis), which Dr. Buse called a “paradigm shift” in managing migraines. Erenumab-aooe is the first FDA-approved preventive